Ishara Investments LP Buys Shares of 50,000 Vaxcyte, Inc. $PCVX

Ishara Investments LP bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 50,000 shares of the company’s stock, valued at approximately $2,307,000. Vaxcyte comprises about 2.7% of Ishara Investments LP’s holdings, making the stock its 12th biggest position.

A number of other large investors have also made changes to their positions in the stock. Caligan Partners LP bought a new stake in Vaxcyte in the fourth quarter valued at about $78,660,000. Adage Capital Partners GP L.L.C. lifted its position in shares of Vaxcyte by 418.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,725,000 shares of the company’s stock worth $79,592,000 after purchasing an additional 1,392,000 shares in the last quarter. Polar Capital Holdings Plc lifted its position in shares of Vaxcyte by 302.6% during the fourth quarter. Polar Capital Holdings Plc now owns 1,672,783 shares of the company’s stock worth $77,182,000 after purchasing an additional 1,257,253 shares in the last quarter. Norges Bank bought a new position in Vaxcyte in the fourth quarter valued at approximately $56,703,000. Finally, Deep Track Capital LP boosted its stake in Vaxcyte by 39.5% in the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock valued at $108,060,000 after acquiring an additional 850,000 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Stock Up 2.8%

Vaxcyte stock opened at $50.67 on Thursday. Vaxcyte, Inc. has a 12-month low of $29.08 and a 12-month high of $65.00. The firm’s fifty day moving average is $53.74 and its 200 day moving average is $52.69. The company has a market capitalization of $7.32 billion, a PE ratio of -7.36 and a beta of 1.24.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the previous year, the business posted ($1.04) EPS. Sell-side analysts expect that Vaxcyte, Inc. will post -7.56 EPS for the current fiscal year.

Insider Buying and Selling

In other Vaxcyte news, CAO Elvia Cowan sold 3,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total transaction of $180,000.00. Following the completion of the sale, the chief accounting officer directly owned 28,975 shares in the company, valued at $1,738,500. The trade was a 9.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $49.52, for a total transaction of $111,420.00. Following the transaction, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. This trade represents a 1.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,500 shares of company stock valued at $419,288 over the last 90 days. 3.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

PCVX has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. BTIG Research lifted their price objective on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.